SANGAMO THERAPEUTICS

Company snapshot

For Sangamo Therapeutics, science is a means to develop new medicines with the potential to transform the lives of patients living with serious genetic diseases. Our scientists are leaders in the discovery, research and development of technologies enabling gene-based therapeutic development. Currently we are conducting clinical trials, including the first ever in vivo human genome editing studies.

• 25 active pipeline program(s) linked via ClinicalTrials.gov.
• 192 US patent(s) indexed to this assignee profile.
• 25 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for SANGAMO THERAPEUTICS. Not investment advice.

• Peer + 0 momentum

  vTv Therapeutics

  TA overlap score 22.8

• Peer + 0 momentum

  Eledon Pharmaceuticals

  TA overlap score 21.8

Recent activity

Latest pipeline, patent, and corporate events for SANGAMO THERAPEUTICS.

1. Jun 8, 2026 Clinical update

   ST-920 — Phase 2

2. Jun 8, 2026 Clinical update

   ST-920 — Phase 2

3. Jun 8, 2026 Clinical update

   ZFN modified T cells — Phase 1

4. Jun 8, 2026 Clinical update

   SB-728mR-HSPC Infusion 3 days following busulfan conditioning — Phase 1

5. Jun 8, 2026 Clinical update

   SB-728-T — Phase 2

View all clinical trial activity →

• What is SANGAMO THERAPEUTICS?

  Sangamo Therapeutics is a biotech organization headquartered in Brisbane, USA. It trades on NYSE under ticker SGMO. Primary therapeutic focus areas include Fabry Disease (X-linked lysosomal storage disease)., Kidney Transplant Rejection, Alzheimer's Disease, Idiopathic Parkinson'

• Is SANGAMO THERAPEUTICS publicly traded?

  Yes. SANGAMO THERAPEUTICS is listed with ticker SGMO on NYSE per SEC EDGAR records linked on this profile.

• What drugs does SANGAMO THERAPEUTICS develop or market?

  We link 14 drug profile(s) where SANGAMO THERAPEUTICS is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/sangamo-therapeutics-inc#company-drugs.

• What are the latest developments for SANGAMO THERAPEUTICS?

  In the last 12 months our linked public records show 25 trial program update(s) and 1 US patent grant(s) tied to this profile.

• What therapeutic areas does SANGAMO THERAPEUTICS focus on?

  SANGAMO THERAPEUTICS focuses on Fabry Disease (X-linked lysosomal storage disease)., Kidney Transplant Rejection, Alzheimer's Disease based on our analysis of their pipeline programs and drug development activities.